Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography

被引:30
作者
Hoerster, Robert [1 ]
Muether, Philipp S. [1 ]
Hermann, Manuel M. [1 ]
Koch, Konrad [1 ]
Kirchhof, Bernd [1 ]
Fauser, Sascha [1 ]
机构
[1] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany
关键词
MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; BEVACIZUMAB; MACULOPATHY; PREVALENCE;
D O I
10.1136/bjo.2010.201129
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
Background Different tests were applied to test the sensitivity of patient self-control; Amsler grid and visual acuity (VA) assessment, as well as fundus examinations to reveal recurrent choroidal neovascularisation (CNV) activity in age-related macular degeneration as detected by spectral domain optical coherence tomography (SD-OCT) in monthly controls. Methods A prospective interventional case series of patients with exudative age-related macular degeneration was examined, which received ranibizumab injections until complete resolution of fluid in SD-OCT. Analysis of changes in subjective perception, Amsler grid, early treatment diabetic retinopathy study (ETDRS) VA, Radner reading VA and fundus examination was conducted in the case of OCT-confirmed CNV recurrences. Results Out of 40 morphological recurrences determined by SD-OCT, six (15%) were noticed by subjective patient perception. Amsler grid testing revealed deterioration in 12 cases (30%); 11 recurrences (28%) were accompanied by loss of >= 5 letters in ETDRS VA and/or >= 1 line in Radner VA; fundus examination showed signs of novel CNV activity in 10 out of 40 recurrences (25%). The combined sensitivity of all diagnostic methods compared to SD-OCT for recurrence detection was 67.5% (27 out of 40 recurrences). Conclusion Subjective patient perception, Amsler grid, VA as well as fundus examination lead to pronounced underestimations of CNV recurrences. Morphologic recurrences can be detected prior to functional deterioration. As any delay of treatment can result in irreversible vision loss, attempts should be made to provide monthly OCT controls to detect recurrences as early as possible.
引用
收藏
页码:1424 / 1426
页数:3
相关论文
共 18 条
[1]
Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study [J].
Augood, C ;
Fletcher, A ;
Bentham, G ;
Chakravarthy, U ;
de Jong, PVTM ;
Rahu, M ;
Seland, J ;
Soubrane, G ;
Tomazzoli, L ;
Topouzis, F ;
Vioque, J ;
Young, I .
OPHTHALMIC EPIDEMIOLOGY, 2004, 11 (02) :117-129
[2]
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study [J].
Bashshur, Ziad F. ;
Haddad, Zeina A. ;
Schakal, Alexandre ;
Jaafar, Rola F. ;
Saab, Marc ;
Noureddin, Baha' N. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (02) :249-256
[3]
Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study [J].
Bashshur, Ziad F. ;
Haddad, Zeina A. ;
Schakal, Alexandre R. ;
Jaafar, Rola F. ;
Saad, Alain ;
Noureddin, Baha' N. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) :59-65
[4]
Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
[5]
Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[6]
FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
[7]
Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
[8]
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration [J].
Fung, Anne E. ;
Lalwani, Geeta A. ;
Rosenfeld, Philip J. ;
Dubovy, Sander R. ;
Michels, Stephan ;
Feuer, William J. ;
Puliafito, Carmen A. ;
Davis, Janet L. ;
Flynn, Harry W., Jr. ;
Esquiabro, Maria .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (04) :566-583
[9]
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact [J].
Gupta, Omesh P. ;
Shienbaum, Gary ;
Patel, Avni H. ;
Fecarotta, Christopher ;
Kaiser, Richard S. ;
Regillo, Carl D. .
OPHTHALMOLOGY, 2010, 117 (11) :2134-2140
[10]
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study [J].
Lalwani, Geeta A. ;
Rosenfeld, Philip J. ;
Fung, Anne E. ;
Dubovy, Sander R. ;
Michels, Stephen ;
Feuer, William ;
Davis, Janet L. ;
Flynn, Harry W., Jr. ;
Esquiabro, Maria .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) :43-58